Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02025231 : Image Guided Reirradiation of High-grade Glioma
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- recurrent high-grade glioma

- previous focal radiotherapy for high-grade glioma

- no standard treatment options available/indicated

- ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1 or 2

- life expectancy > 3 months

- hemoglobin value > 6 mmol/l (transfusion permitted)

- able to understand oral and written Danish

Exclusion Criteria:

- disseminated recurrent disease

- infection or wound dehiscence or other pathological condition in meninges/skull/scalp

- symptoms of elevated intracranial pressure

- very early recurrence following primary radiotherapy (< or equal to 3 months)

- contraindications to magnetic resonance imaging (MRI) or positron emission tomography
(PET)

- other previous radiotherapy to the brain than primary course of irradiation
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02025231      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740